LONDON (Reuters) - Simon Lowth may only be the interim chief executive of AstraZeneca Plc but he is ready to sign off on bold deals. The decision to pair up with Bristol-Myers Squibb Co to buy diabetes specialist Amylin Pharmaceuticals Inc shows the Anglo-Swedish drugmaker is stepping up its deal-making, despite the management hiatus at the top of the company. AstraZeneca is chipping in $3.4 billion for a half share in Amylin's products for the fast-growing type 2 diabetes market. ... Get the complete story
No comments:
Post a Comment